We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
tRF-Leu reverse breast cancer cells chemoresistance by regulation of BIRC5.
- Authors
Sun, Li; Jiao, Yu-Wen; Cui, Fu-Qi; Liu, Jin; Xu, Zhong-Ya; Sun, Dong-Lin
- Abstract
Objective: Accumulating studies reported the crucial roles of tRFs in tumorigenesis. However, their further mechanisms and clinical values remains unclear. This study aimed at the further investigation of tRF-Leu in breast cancer chemotherapy resistance. Methods: The high-throughput sequencing was performed and identified the downregulation of tRF-Leu in MCF7/ADR cells. The function of tRF-Leu in breast cancer cells and breast cancer chemotherapy resistance was investigated in vitro and in vivo, including colony formation assay, CCK-8 assay, transwell assay and apoptosis assay. The binding site of tRF-Leu on BIRC5 was verified by dual-luciferase assay. Results: tRF-Leu was downregulated in MCF7/ADR cells. Overexpression of tRF-Leu inhibited the migration of breast cancer cells. Furthermore, tRF-Leu could reverse the resistance of MCF7/ADR cells to Adriamycin both in vitro and in vivo. BIRC5 was a target of tRF-Leu, which might be involved in the chemotherapy resistance regulation. Conclusion: We demonstrated that tRF-Leu could inhibit the chemotherapy resistance of breast cancer by targeting BIRC5. These findings might identify new biomarkers of breast cancer therapy and bring new strategies to reverse chemotherapy resistance.
- Publication
Discover Oncology, 2024, Vol 15, Issue 1, p1
- ISSN
2730-6011
- Publication type
Article
- DOI
10.1007/s12672-024-01317-1